Prediction of short-term progression of COVID-19 pneumonia based on chest CT artificial intelligence: during the Omicron epidemic.

Prediction of short-term progression of COVID-19 pneumonia based on chest CT artificial intelligence: during the Omicron epidemic.

Publication date: Jun 17, 2024

The persistent progression of pneumonia is a critical determinant of adverse outcomes in patients afflicted with COVID-19. This study aimed to predict personalized COVID-19 pneumonia progression between the duration of two weeks and 1 month after admission by integrating radiological and clinical features. A retrospective analysis, approved by the Institutional Review Board, encompassed patients diagnosed with COVID-19 pneumonia between December 2022 and February 2023. The cohort was divided into training and validation groups in a 7:3 ratio. A trained multi-task U-Net network was deployed to segment COVID-19 pneumonia and lung regions in CT images, from which quantitative features were extracted. The eXtreme Gradient Boosting (XGBoost) algorithm was employed to construct a radiological model. A clinical model was constructed by LASSO method and stepwise regression analysis, followed by the subsequent construction of the combined model. Model performance was assessed using ROC and decision curve analysis (DCA), while Shapley’s Additive interpretation (SHAP) illustrated the importance of CT features. A total of 214 patients were recruited in our study. Four clinical characteristics and four CT features were identified as pivotal components for constructing the clinical and radiological models. The final four clinical characteristics were incorporated as well as the RS_radiological model to construct the combined prediction model. SHAP analysis revealed that CT score difference exerted the most significant influence on the predictive performance of the radiological model. The training group’s radiological, clinical, and combined models exhibited AUC values of 0. 89, 0. 72, and 0. 92, respectively. Correspondingly, in the validation group, these values were observed to be 0. 75, 0. 72, and 0. 81. The DCA curve showed that the combined model exhibited greater clinical utility than the clinical or radiological models. Our novel combined model, fusing quantitative CT features with clinical characteristics, demonstrated effective prediction of COVID-19 pneumonia progression from 2 weeks to 1 month after admission. This comprehensive model can potentially serve as a valuable tool for clinicians to develop personalized treatment strategies and improve patient outcomes.

Open Access PDF

Concepts Keywords
February Adult
Lasso Aged
Models Artificial Intelligence
Pneumonia Computed tomography
Rs_radiological COVID-19
COVID-19
Disease Progression
Female
Humans
Lung
Male
Middle Aged
Prognosis analysis
Retrospective Studies
Risk factors
SARS-CoV-2
SARS-CoV-2
Tomography, X-Ray Computed

Semantics

Type Source Name
disease MESH COVID-19
disease MESH pneumonia
drug DRUGBANK Flunarizine
disease IDO algorithm
drug DRUGBANK Saquinavir
drug DRUGBANK Dichloroacetic Acid
disease VO effective
disease MESH Long Covid
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH infection
disease MESH pulmonary edema
disease MESH syndrome
disease VO organ
disease MESH death
disease MESH sequelae
drug DRUGBANK Trestolone
disease VO time
disease VO population
drug DRUGBANK Coenzyme M
disease IDO history
disease MESH malignancy
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH co infection
disease VO Bacteria
disease VO Viruses
disease VO leukocyte
disease VO erythrocyte
disease VO protocol
disease MESH Clinical progression
disease VO dose
disease MESH pleural effusion
disease MESH emphysema
disease MESH bronchiectasis
disease MESH pericardial effusion
disease VO volume
drug DRUGBANK Esomeprazole
disease MESH hypertension
disease MESH chronic diseases
disease MESH causes
disease IDO immune response
disease MESH organizing pneumonia
disease IDO process
disease MESH critical illness
disease MESH lung injury
disease MESH inflammation
disease MESH edema
disease MESH heart failure
drug DRUGBANK Fenamole
disease MESH viral infections
disease VO company
disease VO organization
drug DRUGBANK Troleandomycin
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH viral pneumonia
disease IDO cell
drug DRUGBANK Dexfenfluramine
drug DRUGBANK Guanosine
disease MESH Lymphopenia
disease MESH Allergy

Original Article

(Visited 2 times, 1 visits today)